Improvement of Syndromic Screening of Respiratory and Enteric Pathogens with Rapid PCR Cycling Genetic Signatures presents optimised cycling times for six key EasyScreenTM respiratory and gastrointestinal detection kits, enabling faster time-to-result to support laboratory workflow and reporting, and improved patient management.

Genetic Signatures’ CEO Dr John Melki was recently interviewed by Nadine Blayney from AusBiz about the Company’s unique 3base® technology, its advantages for detecting infectious diseases, the development pipeline, revenue sources, and plans for further investment and expansion in key international markets.

Genetic Signatures’ CEO Dr John Melki takes part in the Biotech Predictions webinar, discussing the company’s recent financial summary, our ongoing response to the COVID-19 pandemic, and further global impact with products including gastrointestinal infection and sexual health testing.

Hear from our Senior Principal Research Scientist, Dr Rohan Baker, in this years’ virtual NRL Workshop on Infectious Diseases. The talk and Q&A discusses the validation of our EasyScreen SARS-CoV-2 Detection Kit on saliva samples, in collaboration with St Vincent’s Health Network Sydney.